Download PDF
Thromb Haemost 2002; 88(05): 875-877
DOI: 10.1055/s-0037-1613319
Letters to the Editor
Schattauer GmbH

Allele Frequencies of Tissue Factor Pathway Inhibitor Polymorphisms in African-American, Hispanic and Caucasian Populations

Gabriele I. Mues
1   Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX, USA
,
Ravindra Sarode
1   Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX, USA
› Author Affiliations
Further Information

Publication History

Received 25 June 2002

Accepted 02 July 2002

Publication Date:
08 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Girard T-J, Warren L-A, Novotny W-F. et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1998; 338: 518-20.
    PubMedGoogle Scholar
  • 2 Bajaj M-S, Birktoft J-J, Steer S-A, Bajaj S-P. Structure and biology of tissue factor pathway inhibitor. Review. Thromb Haemost 2001; 86: 959-72.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Osterud B, Bajaj M-S, Bajaj S-P. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. Thromb Haemost 1995; 73: 873-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Moatti D, Seknadji P, Galand C. et al. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects. Arterioscler Thromb Vasc Biol 1999; 19: 862-9.
    CrossrefPubMedGoogle Scholar
  • 5 Amini-Nekoo A, Futers T-S, Moia M, Mannucci P-M, Grant P-J, Ariens R-A-S. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. British J Haematol 2001; 113: 537-43.
    CrossrefPubMedGoogle Scholar
  • 6 Kleesiek K, Schmidt M, Gotting C. et al. The 536→C transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis. Thromb Haemost 1999; 82: 1-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Paciaroni K, Rossi E, Bazzan M, Ireland H, De Stefano V. Prevalence of the C536T mutation in the tissue factor pathway inhibitor (TFPI) gene among patients with venous thrombotic disease. Thromb Haemost 2001; 85: 938-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Gonzales-Conejero R, Lozano M-L, Corral J, Martinez C, Vicente V. The TFPI 536 C→T mutation is not associated with increased risk for venous or arterial thrombosis. Thromb Haemost 2000; 83: 787-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Hessner M-J, Luhm R-A. The C536T transition in the tissue factor pathway inhibitor (TFPI) gene does not contribute to risk of venous thrombosis among carriers of factor V Leiden. Thromb Haemost 2000; 84: 724-5.
    Article in Thieme ConnectPubMedGoogle Scholar